A recent study has shown the role of ATRX as an epigenetic regulator in glioma development [42], whereas the effects of ATRX mutations in ALTs, a non-telomerase-dependent telomere lengthening mechanism, are well established [43–46]. Here, ATRX is linked to central nervous system cancer.